Primo Medical Group and Management Acquire Arthrosurface from Anika Therapeutics

ARCHIMED Acquires WiQo S.p.A.

March 9, 2023

Medical Devices

ARCHIMED, a Europe-based healthcare private equity firm, has acquired WiQo, an Italian developer and manufacturer of the PRX‑T33 topical biostimulator used in aesthetic medicine. Founders (Dr. Rossana Castellana and family) retained a 25% stake and Castellana will stay on to lead R&D; the deal was financed with debt provided by Banco BPM and Crédit Agricole Italia and is the fourth investment from ARCHIMED's MED III fund.

SyAqua (Ocean 14 Capital) Acquires Primo Broodstock

July 16, 2024

Agriculture

Singapore-based shrimp genetics company SyAqua, which is majority-owned by Luxembourg-headquartered private equity firm Ocean 14 Capital, has acquired Mims, Florida–based Primo Broodstock. The acquisition expands SyAqua’s U.S. broodstock production capacity and genetic resources, enhancing strain security and enabling increased supply to major shrimp-producing markets.

Oakley Capital Acquires PRIMAVERA and Creates Grupo Primavera with Ekon

June 22, 2021

Software

Oakley Capital Private Equity III has agreed to acquire PRIMAVERA Business Software Solutions, the Portuguese leader in ERP and business management software, from founders José Dionísio and Jorge Batista. The business will be combined with Oakley’s existing portfolio company Ekon and recent bolt-ons to form Grupo Primavera, a leading independent Iberian SME software platform focused on accelerating SaaS adoption.

Sobi Acquires Arthrosi Therapeutics

February 9, 2026

Biotechnology

Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of Arthrosi Therapeutics, acquiring all outstanding shares and adding pozdeutinurad (AR882), an investigational once-daily oral URAT1 inhibitor in two fully enrolled Phase 3 trials. The acquisition strengthens Sobi's gout franchise and pipeline; Arthrosi is headquartered in San Diego and rights to pozdeutinurad in Greater China are held by ApicHope. Pivotal Phase 3 data from REDUCE 1 and REDUCE 2 are expected in 2026.

ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera

November 17, 2023

Healthcare Services

ARCHIMED has acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and merged them to create Symbio Proinnovera, a specialized dermatology-focused CRO. The combined group will offer end-to-end dermatology consulting, formulation, testing and clinical research across North America and Europe, with founders rolling equity into the new platform and ARCHIMED-appointed operating partners joining the board to drive growth and further acquisitions.

Primus Capital Invests in Prendio and BioProcure

October 18, 2023

Cloud & SaaS

Primus Capital has made a growth equity investment in Prendio and sister company BioProcure to support organic growth, expansion into additional life-sciences markets, and continued product and service innovation. The investment will back Prendio's cloud-based eProcurement SaaS and BioProcure's procure-to-pay support services for biotech customers; Aeris Partners served as exclusive financial advisor to the sellers and law firms Latham & Watkins and Goodwin Proctor served as legal advisors.